the tumor adds more challenges and makes partial nephrectomy less likely to be considered.
INTRODUCTION AND OBJECTIVES:
Tumor seeding or intraperitoneal spread of disease occurs rarely after percutaneous biopsy or ablation of renal cell carcinoma. We present a case of robot-assisted cytoreductive nephrectomy and resection of pelvic metastasis after percutaneous cryoablation of renal cell carcinoma.
METHODS: A 69 year old male was referred to City of Hope with a prior history of percutaneous cryoablation of a 3 cm biopsyproven clear cell renal cell carcinoma. At 4 and 9 months after ablation, CT scan showed no evidence of disease recurrence. At 13 months after surgery, a CT showed a 3 cm renal mass suspicious for recurrent cancer and a 3.8 cm mass involving the right seminal vesicle. Pulmonary metastases were also found. CT-guided biopsy of both masses confirmed renal cell carcinoma.
RESULTS: After discussion of treatment options, cytoreductive robot-assisted left radical nephrectomy with pelvic mass resection was performed. The renal cancer was adherent to the colonic mesentery and the mesentery was widely resected in this area. After nephrectomy was complete, the patient was re-positioned into dorsal lithotomy position and the pelvic mass was resected. The right seminal vesicle was resected in order to ensure that the disease was completely resected. The postoperative course was uncomplicated and the patient was discharged on postoperative day 2. Final pathology results demonstrated pT4 grade 4 clear cell renal cell carcinoma with sarcomatoid features, locally invading the colonic mesentery. CONCLUSIONS: Though rare, pelvic metastasis may occur after cryoablation of renal cell carcinoma. Robot-assisted techniques may be applied in this situation. INTRODUCTION AND OBJECTIVES: Ischemia reperfusion injury is associated with serious inflammatory responses. Inflammation triggers mononuclear cells to migrate through vessel walls leading to tissue damage. We aimed to investigate the effect of the early application of Everolimus and Sirolimus on the vascular response of human vessels after ischemia and posterior reperfusion, which is quite nesseccary for kidney transplantation and ischemia time during kindey operation.
Source of Funding: None
METHODS: Human vessels (saphenous vein/internal thoracic artery segments) were obtained after informed consent and Ethics approval. The vessels were preserved in a NaCl/Heparin solution and after 4 h ischemia connected to a customized bioreactor consisting on a double roller-pump with oxygenator and reperfused for 120 min with compatible human blood. The vessels were treated with Everolimus (10 ng/ml Certican, Novartis, Switzerland) or Sirolimus (10 ng/ml Rapamune, Pfizer, USA). Untreated vessels served as control group. Blood samples were obtained during the reperfusion and biopsies at the end of the experiment. Vitality of the vessels was measured through oxygen consumption during reperfusion. Inflammatory cytokines (IL-6, TNF-alpha) as well as VEGF were analyzed by ELISA. Immunohistochemical analysis of CD11 and CD31 was performed to evaluate the vascular inflammation.
RESULTS: Vitality of the vessels could be demonstrated with adequate oxygen consumption and stable pH values. Treatment with Everolimus showed a significant reduction of IL-6 in comparison to Sirolimus and control vessels, and of TNF-alpha compared to Sirolimus at the end of the reperfusion. No differences regarding the concentration of VEGF were observed. Immunohistochemistry showed a significant reduction of positive reactions to CD11b and CD31 in both mTORs compared to control vessels.
CONCLUSIONS: Early treatment with mTOR inhibitors, especially Everolimus, may prevent the pro-inflammatory reaction after ischemic injury. Both Everolimus and Sirolimus reduce the cellular infiltration and the vascular response after reperfusion. 
